ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
December 12, 2023 05:15 ET
|
ADC Therapeutics SA
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC...
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
December 07, 2023 19:51 ET
|
EnGeneIC
EneneIC has been granted Fast Track designation for use of its novel Armed Nanocell Drug Conjugate (ANDC) in PDAC patients.
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung
November 29, 2023 08:30 ET
|
Oxford BioTherapeutics
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein DLL3 antigen was discovered using OBT’s proprietary OGAP® drug discovery...
EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options
November 26, 2023 23:37 ET
|
EnGeneIC
SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious...
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
November 20, 2023 10:00 ET
|
Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
Data Converter Market Size worth $8.28 Billion, Globally, by 2028 - Exclusive Report by The Insight Partners
November 10, 2023 11:45 ET
|
The Insight Partners
Pune, India., Nov. 10, 2023 (GLOBE NEWSWIRE) -- According to a new report published by The Insight Partners on “Data Converter Market Size and Forecast (2022–2028), Global and Regional Share,...
November is Pancreatic Cancer Awareness Month
November 08, 2023 04:00 ET
|
EnGeneIC
SYDNEY, Australia and NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pancreatic ductal adenocarcinoma (PDAC), which accounts for >90% of pancreatic tumors, is one of the most lethal malignancies and...
ADC Therapeutics nimmt an der Jefferies London Healthcare Conference teil
November 06, 2023 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Schweiz, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass Ameet Mallik, Chief Executive Officer, auf der Jefferies London Healthcare Conference am...
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 06, 2023 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...
MacroGenics to Participate in Upcoming Investor Conferences
November 02, 2023 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...